Insight Molecular Diagnostics Inc. (IMDX) Stock

Insight Molecular Diagnostics Inc. (IMDX) is a Healthcare stock trading at $5.46 (as of 2026-06-18), with a market capitalization of $200.52M and a trailing P/E of -3.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Insight Molecular Diagnostics Inc. offers proprietary laboratory-developed molecular tests for cancer detection, including DetermaRx for early-stage lung adenocarcinoma and DetermaIO gene expression assays. It also supports biomarker discovery, assay design and development, and clinical trial services, with offerings for pharmaceutical companies and a collaboration with Life Technologies for assay use with Ion Torrent Genexus.

Valuation — source: SEC EDGAR (first-party)
Price	$5.46
Market Cap	$200.52M
P/E Ratio	-3.6
EV / EBITDA	-3.2
Price / Book	-16.43
Price / Sales	90.13
DCF Value (model)	$-13.07
DCF Upside vs Price	-339.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.05M
Net Margin	-1238.5%
Return on Equity	447.5%
Current Ratio	2.54
Revenue Growth (YoY)	-98.5%
EPS Growth (YoY)	-53.8%
FCF Growth (YoY)	33.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	-26.18 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-117.2%
vs Industry	-120.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BROADWOOD CAPITAL INC ($39.14M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Joshua Riggs
Employees	46
Country	US
IPO Date	2015-12-30

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.